Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In A Win For Amgen, Court Blocks Sanofi/Regeneron's Praluent Sales In Germany

Executive Summary

A court in Dusseldorf ruled that Praluent infringes a patent for Amgen's better-selling PCSK9 inhibitor Repatha, saying that Sanofi and Regeneron must stop selling their biologic in Germany. It's unclear whether there will be any readthrough to ongoing patent disputes in other countries.

Advertisement

Related Content

Heralding Change: Product Pipeline Advances To Watch Out For In Q3
The Medicines Co. CEO Timney On Selling Inclisiran And Why Big Pharma Is Still Interested In CV Disease
Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
PCSK9 Patent Case: Praluent Injunction Vacated, But May Well Return
Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel